{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T11:08:16Z","timestamp":1780657696595,"version":"3.54.1"},"reference-count":55,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Abbvie, Lda"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Chronic lymphocytic leukaemia (CLL) is the most common leukaemia among adults in western countries. Considering the increasing incidence and prevalence of this condition, it is highly relevant to better characterise these patients in Portugal, where data is still scarce.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>To determine incidence, clinical presentation, survival and second malignancies, a population-based historical cohort study was conducted. Cases of interest were identified through the South Region Cancer Registry database and additional data sources. Patients aged \u226518\u2009years, with a confirmed diagnosis of CLL or small lymphocytic lymphoma between January 1<jats:sup>st<\/jats:sup>, 2013 and December 31<jats:sup>st<\/jats:sup>, 2014 were included. Patients were followed\u2010up until death or cut-off date (December 31<jats:sup>st<\/jats:sup>, 2019).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 496 patients were included and median follow-up time was 5.46 years. Crude incidence rates were 5.03 and 5.22 per 100,000 inhabitants for 2013 and 2014, respectively, and age-adjusted incidence rates were 3.18:100,000 European population for 2013 and 3.35:100,000 European population for 2014. Median age at diagnosis was 71 years and the male\/female ratio was 1.40. The majority of patients had leukemic presentation of the disease (86.09%), was diagnosed in Binet stage A (75.58%) and did not present B symptoms (84.01%), anaemia (haemoglobin \u226410g\/dL; 90.63%) nor thrombocytopenia (platelet count \u2264100 000\/\u03bcL; 91.73%). Five-year overall survival (OS) rate was 70.53% (95%CI 66.31\u201374.34) and age, lactate dehydrogenase, Binet stage and a \u22655 Charlson comorbidity index score were independently associated with OS. Standardised-incidence ratios for any second malignancy and cutaneous squamous cell carcinoma were 1.59 (95%CI 1.19\u20132.08) and 10.15 (95%CI 6.28\u201315.51), respectively.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Incidence, clinical presentation and survival of CLL Portuguese patients are similar to those reported for other western countries. The increased risk of second malignancies raises concerns and needs adequate clinical watchfulness.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0258423","type":"journal-article","created":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T22:25:37Z","timestamp":1633818337000},"page":"e0258423","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Detailing the epidemiological and clinical characteristics of chronic lymphocytic leukaemia in Portugal\u2014Results from a population-based cancer registry cohort study"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8496-9211","authenticated-orcid":true,"given":"F\u00e1bio","family":"Cardoso Borges","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1316-0209","authenticated-orcid":true,"given":"Adriana","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f3nio","family":"Louren\u00e7o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gomes da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the ROR-Sul network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,10,8]]},"reference":[{"issue":"3","key":"pone.0258423.ref001","article-title":"Chronic lymphocytic leukaemia","volume":"19","author":"T Kipps","year":"2017","journal-title":"Nat Rev Dis Prim"},{"key":"pone.0258423.ref002","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.critrevonc.2016.06.003","article-title":"Chronic lymphocytic leukaemia","volume":"104","author":"L Scarf\u00f2","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"pone.0258423.ref003","volume-title":"WHO Classification of Tumours of Heamatopoietic and Lymphoid Tissues","author":"S Swerdlow","year":"2008"},{"key":"pone.0258423.ref004","unstructured":"National Cancer Institute. Cancer Stat Facts: Leukemia\u2014Chronic Lymphocytic Leukemia (CLL) [Internet]. Surveillance, Epidemiology, and End Results Program (SEER). [cited 2020 Dec 14]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html."},{"issue":"12","key":"pone.0258423.ref005","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"M Hallek","year":"2008","journal-title":"Blood"},{"issue":"25","key":"pone.0258423.ref006","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"M Hallek","year":"2018","journal-title":"Blood"},{"issue":"20","key":"pone.0258423.ref007","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"SH Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"2","key":"pone.0258423.ref008","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"K Rai","year":"1975","journal-title":"Blood"},{"issue":"1","key":"pone.0258423.ref009","doi-asserted-by":"crossref","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"J Binet","year":"1981","journal-title":"Cancer"},{"issue":"6","key":"pone.0258423.ref010","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3109\/10428199609054782","article-title":"Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma","volume":"5","author":"M. Hallek","year":"1996","journal-title":"Leuk Lymphoma"},{"issue":"343","key":"pone.0258423.ref011","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"28","author":"H Dohner","year":"2000","journal-title":"N Engl J Med"},{"issue":"4","key":"pone.0258423.ref012","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416","article-title":"mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia","volume":"100","author":"A Kr\u00f6ber","year":"2002","journal-title":"Blood"},{"issue":"6","key":"pone.0258423.ref013","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1182\/blood.V99.6.2262","article-title":"Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia","volume":"99","author":"G Tobin","year":"2002","journal-title":"Blood"},{"issue":"31","key":"pone.0258423.ref014","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1200\/JCO.2010.33.9002","article-title":"Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia","volume":"29","author":"WG Wierda","year":"2011","journal-title":"J Clin Oncol"},{"key":"pone.0258423.ref015","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2008-04-154070","article-title":"Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up","volume":"112","author":"T Zenz","year":"2008","journal-title":"Blood"},{"issue":"6","key":"pone.0258423.ref016","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"The International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytc leukaemia (CLL-IPI): a meta analysis of individual patient data","volume":"17","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"pone.0258423.ref017","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/10428194.2019.1680840","article-title":"Survival improvement of patients with chronic lymphocytic leukemia (CLL) in routine care 1995\u20132017","volume":"61","author":"R Weide","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"21","key":"pone.0258423.ref018","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/bloodadvances.2018023895","article-title":"Venous thromboembolism in chronic lymphocytic leukemia: a Danish nationwide cohort study","volume":"2","author":"I Gade","year":"2018","journal-title":"Blood Adv"},{"issue":"6","key":"pone.0258423.ref019","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/ejh.13396","article-title":"Chronic lymphocytic leukemia and secondary hematological malignancies: A nation-wide cancer registry study","volume":"104","author":"A Lenartova","year":"2020","journal-title":"Eur J Haematol"},{"issue":"9596","key":"pone.0258423.ref020","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"E von Elm","year":"2007","journal-title":"Lancet"},{"key":"pone.0258423.ref021","unstructured":"Silva I. Principles and methods: cancer epidemiology. Geneva; 1999."},{"key":"pone.0258423.ref022","unstructured":"World Health Organization. International Classification of Diseases for Oncology (ICD-O), 3rd Edition 1st revision. 2013."},{"issue":"5","key":"pone.0258423.ref023","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"M Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"pone.0258423.ref024","author":"S. Ferreti","year":"2009","journal-title":"Airtum cancer registration handbook"},{"key":"pone.0258423.ref025","unstructured":"Instituto Nacional de Estat\u00edstica. Resident population by place of residence (NUTS\u20142013), sex and age group, annual, 2013 and 2014."},{"key":"pone.0258423.ref026","unstructured":"Eurostat. Revision of the European Standard population: report of the Eurostat\u2019s task force. Luxembourg; 2013."},{"key":"pone.0258423.ref027","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/CLEP.S129785","article-title":"Missing data and multiple imputation in clinical epidemiological research,\u201d Clinical epidemiology","volume":"6","author":"A Pedersen","year":"2017","journal-title":"Clin Epidemiol"},{"key":"pone.0258423.ref028","volume-title":"Stata Statistical Software: Release 13","author":"StataCorp","year":"2013"},{"issue":"3","key":"pone.0258423.ref029","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10552-018-1004-5","article-title":"Challenges in assessing the real incidence of chronic lymphocytic leukemia: 16 years of epidemiological data from the province of Girona, Spain","volume":"29","author":"M Solans","year":"2018","journal-title":"Cancer Causes Control"},{"issue":"11","key":"pone.0258423.ref030","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.leukres.2009.06.013","article-title":"High incidence of chronic lymphocytic leukemia (CLL) diagnosed by immunophenotyping: A population-based Canadian cohort.","volume":"33","author":"MD Seftel","year":"2009","journal-title":"Leuk Res."},{"issue":"4","key":"pone.0258423.ref031","first-page":"171","article-title":"Chronic lymphocytic leukemia in Iceland from 2003 to 2013: Incidence, presentation and diagnosis","volume":"102","author":"G Olafsson","year":"2016","journal-title":"Laeknabladid"},{"key":"pone.0258423.ref032","unstructured":"The Surveillance Epidemiology and End Results (SEER) Program of the National Cancer institute. Cancer fact sheets: chronic lymphocytic leukemia (CLL)."},{"issue":"3","key":"pone.0258423.ref033","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00277-014-2217-7","article-title":"Trends in incidence and medical resource utilisation in patients with chronic lymphocytic leukaemia: insights from the UK Clinical Practice Research Datalink (CPRD)","volume":"94","author":"A Pfeil","year":"2014","journal-title":"Ann Hematol"},{"key":"pone.0258423.ref034","first-page":"E36","article-title":"Increasing prevalance of chronic lymphocytic leukemia with an estimated future rise: A nationwide population-based study","author":"M Mattson","year":"2019","journal-title":"Am J Hematol"},{"issue":"4","key":"pone.0258423.ref035","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.leukres.2015.01.015","article-title":"Incidence of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis in Calgary, Alberta, Canada","volume":"39","author":"R Healey","year":"2015","journal-title":"Leuk Res"},{"key":"pone.0258423.ref036","unstructured":"Belgian Cancer Registry. Haematological malignancies in Belgium. Brussels; 2015."},{"issue":"12","key":"pone.0258423.ref037","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1002\/cam4.849","article-title":"National trends in incidence and survival of chronic lymphocytic leukemia in Norway for 1953\u20132012: a systematic analysis of population-based data","volume":"5","author":"A Lenartova","year":"2016","journal-title":"Cancer Med"},{"issue":"4","key":"pone.0258423.ref038","doi-asserted-by":"crossref","first-page":"e461","DOI":"10.18295\/squmj.2018.18.04.006","article-title":"Clinical Aspects, Immunophenotypic Analysis and Survival Rate of Chronic Lymphocytic Leukaemia Patients in Erbil City, Iraq","volume":"18","author":"K. Hasan","year":"2018","journal-title":"Sultan Qaboos Univ Med J"},{"issue":"6","key":"pone.0258423.ref039","doi-asserted-by":"crossref","first-page":"E270","DOI":"10.1016\/j.clml.2019.11.002","article-title":"Subtype Distribution, Clinical Features, and Survival in B-cell Chronic Lymphoproliferative Disorders in China: A Review of 1592 Cases","volume":"20","author":"Y Yan","year":"2019","journal-title":"Clin Lymphoma, Myeloma Leuk"},{"issue":"106335","key":"pone.0258423.ref040","article-title":"Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada","volume":"91","author":"S Huang","year":"2020","journal-title":"Leuk Res"},{"issue":"4","key":"pone.0258423.ref041","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3324\/haematol.2018.200204","article-title":"First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013","volume":"104","author":"S Sylvan","year":"2019","journal-title":"Haematologica"},{"issue":"5","key":"pone.0258423.ref042","first-page":"1","article-title":"Epidemiology of Hematologic Malignancies in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study","author":"V Tietsche de Moraes Hungria","year":"2019","journal-title":"J Glob Oncol."},{"key":"pone.0258423.ref043","article-title":"Chronic Lymphocytic Leukemia: Real-World Data From India","volume":"6","author":"V Tejaswi","year":"2020","journal-title":"JCO Glob Oncol"},{"issue":"6","key":"pone.0258423.ref044","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","author":"International CLL-IPI working group","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"pone.0258423.ref045","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/cncr.31738","article-title":"Real-world testing and treatment patterns in chronic lymphocytic leukemia: A SEER patterns of care analysis","volume":"125","author":"E Seymour","year":"2019","journal-title":"Cancer"},{"issue":"5","key":"pone.0258423.ref046","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1532-5415.1968.tb02103.x","article-title":"Cumulative illness rating scale","volume":"16","author":"B Linn","year":"1968","journal-title":"J Am Geriatr Soc"},{"issue":"14","key":"pone.0258423.ref047","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood-2015-10-620864","article-title":"Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis","volume":"127","author":"S Parikh","year":"2016","journal-title":"Blood"},{"issue":"26","key":"pone.0258423.ref048","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1182\/blood-2017-03-772285","article-title":"In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI","volume":"129","author":"G Rigolin","year":"2017","journal-title":"Lett to Blood"},{"issue":"6","key":"pone.0258423.ref049","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3324\/haematol.2013.096792","article-title":"Interactions between comorbidity and treatment of chronic lymphocytic leukemia: Results of German chronic lymphocytic leukemia study group trials","volume":"99","author":"V Goede","year":"2014","journal-title":"Haematologica"},{"issue":"3","key":"pone.0258423.ref050","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.14785","article-title":"Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study","volume":"178","author":"P Strati","year":"2017","journal-title":"Br J Haematol"},{"issue":"1","key":"pone.0258423.ref051","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/ijc.22672","article-title":"Risk of second cancer after chronic lymphocytic leukemia","volume":"121","author":"C Sch\u00f6llkopf","year":"2007","journal-title":"Int J Cancer"},{"issue":"6","key":"pone.0258423.ref052","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1200\/JCO.2008.17.5398","article-title":"Other Malignancies in Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma","volume":"27","author":"A Tsimberidou","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"pone.0258423.ref053","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/bjc.2011.313","article-title":"Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: A population-based study","volume":"105","author":"JA Royle","year":"2011","journal-title":"Br J Cancer"},{"issue":"232\u2013239","key":"pone.0258423.ref054","article-title":"Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia","volume":"185","author":"G Zheng","year":"2019","journal-title":"Br J Haematol"},{"key":"pone.0258423.ref055","article-title":"Risk factors for skin cancer and solid tumors in newly diagnosed patients with chronic lymphocytic leukemia and the impact of skin surveillance on survival","author":"G Ishdorj","year":"2019","journal-title":"Leuk Lymphoma"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0258423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T22:26:40Z","timestamp":1633818400000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0258423"}},"subtitle":[],"editor":[{"given":"Tomoki","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,10,8]]},"references-count":55,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10,8]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0258423","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,8]]}}}